Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Online Resource
    Online Resource
    Oxford University Press (OUP) ; 2020
    In:  Nephrology Dialysis Transplantation Vol. 35, No. Supplement_3 ( 2020-06-01)
    In: Nephrology Dialysis Transplantation, Oxford University Press (OUP), Vol. 35, No. Supplement_3 ( 2020-06-01)
    Abstract: Neutrophil/Lymphocyte Ratio (NLR) and Platelet/Lymphocyte Ratio (PLR) are closely associated with increased inflammation in end-stage renal disease, which often contributes to the severity of anemia in these patients. Erythropoiesis stimulating agents (ESA) have become a standard treatment of anemia in hemodialysis patients. Since some patients do not respond well to erythropoietin therapy (EPO) the aim of this study is to investigate if NLR and PLR as markers of increased inflammation, could be associated with resistance to EPO therapy. Method A total of 90 patients (36 females, 54 males; mean age 60,45 ±11,58) undergoing maintenance hemodialysis and who received recombinant human EPO therapy were examined. Patients' clinical characteristics, laboratory data, dialysis adequacy and the applied doses os EPO were examined in a period of 3 months. EPO hyporesponsiveness index (EHRI) was calculated as the weekly dose of EPO divided by kilograms of body weight divided by the hemoglobin level. Results Obtained results show a statistically significant correlation of moderate-intensity between EHRI and NLR ( r = 0.497, p & lt; 0.01) as well as a negative correlation of moderate-intensity between EHRI and hemoglobin levels (Hgb) (r = -0.403, p & lt; 0.01). When it comes to the connection of NLR and PLR with logarithmically converted EHRI values, the results show that there is no statistically significant correlation between NLR and EHRI. Comparison of PLR among 25th, 50th and 75th percentile of EHRI showed that PLR levels increased going from the 25th towards the 75th percentile (p & lt; 0.01). Post hoc analysis indicated that there is also a statistically strong connection for the 25th i 50th percentile ( & lt;0 .05) and furthermore for the 50th and 75th percentile ( & lt; 0.05). Conclusion PLR was found to be superior to NLR in terms of evaluating ESA therapy resistance. PLR could be used as a predictor of ESA therapy response.
    Type of Medium: Online Resource
    ISSN: 0931-0509 , 1460-2385
    Language: English
    Publisher: Oxford University Press (OUP)
    Publication Date: 2020
    detail.hit.zdb_id: 1465709-0
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    In: Nephrology Dialysis Transplantation, Oxford University Press (OUP), Vol. 36, No. Supplement_1 ( 2021-05-29)
    Abstract: Expended hemodialysis (HDx) with medium cut-off (MCO) membrane enables efficient depuration of middleweight uremic toxins, which play significant roles in inflammation and cardiovascular morbidity. Hemodiafiltration (HDF) is known for good removal of middle molecules but it requires more technical resources and well-functioning dialysis access. The aim of this study is to evaluate the efficacy of depuration of uremic toxins with a high-flux dialyzer during HDF session and with a MCO membrane (Theranova®) in HDx session and its impact on quality of life (QoL) in hemodialysis patients. Method In an open, single-centre, prospective observational clinical study, 28 adult stable HD patients without residual renal function were assigned to be treated by on-line HDF (HDF group) with the APS-21H dialyzer (polysulfone membrane, 2.1 m2, Asahi Kasei Medical Co., Japan) or by HDx (HDx group) with the Theranova® 400 (1.7 m2) and Theranova® 500 (2.0 m2) dialyzers (Baxter International Inc, USA). The study was conducted during 2019-2020 and completed after 12 months period. All patients were receiving maintenance high-flux membrane HDF treatment at least six months before they were enrolled in the study. Groups of patients were matched in age, sex, BMI, dialysis length and underlying disease. Complete blood count (CBC), renal function and inflammation, electrolytes, liver function tests, iron and nutritional status were evaluated at the beginning of the study and after 3, 6, 9 and 12 months. Pre and postdialysis levels for urea, creatinine, albumin, calcium, phosphorus, C-Reactive Protein, kappa and lambda free light chains (FLC), vitamin B12, β2 microglobulin levels were determined in each patient quarterly and reduction rate (RR) for uremic toxins were calculated. Furthermore single-pool Kt/V, dose of erythropoietin therapy (EPO) and vascular access were evaluated during the study, while bioimpedance analysis using Body composition monitor (Fresenius Medical Care, Germany) and QoL using SF-36 questionnaire (Kidney Disease Quality of Life Short Form-KDQOLTM-36) were evaluated at the end of observation period. The values have been reported as mean ±SD. Results There were 28 patients (14 in each group) mean age of 54.24 years (57.71±9.65 in HDx group vs 59.81±7.99 in HDF group). Median dialysis vintage was 4.77 years (5.33 in HDx group vs 6.46 in HDF group, p=0.55). Vascular access was native arteriovenous fistula in 23 patients, arteriovenous graft in 2 patients and tunnelled dialysis catheter in 3 patients (p=0.98). Kt/V was similar in both groups (1.57±0.31 vs 1.45±0.24, p=0.9), as well as weekly dose of EPO (4533.3±1922.3 vs 4233.3±1971.8, p=0.67). Patients in HDF group had a significantly higher interdialysis fluid overload (2,48±1,37 in HDx group vs 3,64±1,33 in HDF group, p=0.04), without difference in relation to the systolic and diastolic blood pressure values, as well as others BCM parameters. There were not significant differences in examined parameters of CBC, renal function and inflammation, electrolytes, liver function tests, iron and nutritional status at the beginning and at the end of the study. RR of small and middle molecules are presented in Table 1. Serum albumin level has decreased from 37.8 g/dL to 36.4 g/dL in 12 months during HDx treatment with maximal change of serum albumin level of -3.7% during that period (Figure 1). Evaluation of Kidney Disease Quality of Life Short Form at the end of study period in both groups is shown in Figure 2. Conclusion Compared to HDF, HDx with MCO membranes show greater RR for large middle molecules such as lambda FLC (45kD), while RRs for middle molecules- kappa FLC (23kD), β2 microglobulin (12kD) and small uremic toxins are similar. During one year of treatment with MCO membranes serum albumin levels remain stable. HDx treatment may improve quality of life, making an impact primarily in energy status and emotional satisfaction.
    Type of Medium: Online Resource
    ISSN: 0931-0509 , 1460-2385
    Language: English
    Publisher: Oxford University Press (OUP)
    Publication Date: 2021
    detail.hit.zdb_id: 1465709-0
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    Online Resource
    Online Resource
    National Library of Serbia ; 2021
    In:  Military Medical and Pharmaceutical Journal of Serbia Vol. 78, No. 7 ( 2021), p. 769-774
    In: Military Medical and Pharmaceutical Journal of Serbia, National Library of Serbia, Vol. 78, No. 7 ( 2021), p. 769-774
    Abstract: Backgraund/Aim. Primary anti-neutrophil cytoplasmatic antibody (ANCA)-associated vasculitis are chronic multisystemic autoimmune diseases which include microscopic polyangitis (MPA), granulomatosis with polyangitis (WG), eosinophilic granulomatosis with polyangitis (EPGA; churg-strauss syndrome ? CSS), and also a localized forms of ill-ness. In our research, we studied clinical and serological parameters in patients, in order to find out which of them would be the best predictor of renal outcome in ANCA-associated vasculitis. Methods. Data from 42 patients with diagnose of MPA (9), WG (17), EPGA (0), CSS (0), and al-so idiopathic rapidly progressive glomerulonephritis (ROEB) without immune deposits (renal-limited vasculitis ? 16) were analyzed. Cockroft formula was used for calculating the glomerular filtration in the moment of presenting the illness, and also after five year follow-up period. Other factors that were analyzed are: gender, age, type of ANCA antibodies, type of infections, stage of chronic kidney dis-ease, need for heamodialysis and mortality. Results. Of a total of 42 patients, 17 (40.48%) were male. The average age of the patients at the time of diagnosis was 57.8 (? 10.44) years. Seventeen patients (40.48%) had a diagnosis of WG, 9 (21.43%) MPA, and 16 (38.09%) iRPGN. The presence of positive anti-proteinase (anti-PR3) antibodies was confirmed i n 1 8 patients, a nd a nti-MPO antibodies in 17 patients. Three patients had both subtypes of ANCA antibodies (anti-PR3 and anti-MPO). Initially, 12 patients required heamodialysis treatment. Twenty nine patients had a complete and 13 patients had partial remission. Out of the total number of patients, 8 patients (19.04%) developed the terminal renal failure stage, and ended up on a chronic dialysis program. During a five-year follow-up period, 12 patients (28.57%) resulted in death. The age of the patient proved to be statistically significant predictor of glomerular filtration rate (GFR) at the moment of presentation of the disease (p = 0.011). GFR t = 0 was statistically significant (p = 0.000) for the evaluation of kidney function outcomes in ANCA-associated glomerulonephritis. Conclusion. Kidney function in the moment of illness presentation, determined by GFR t = 0, is the most important significant factor for predicting renal outcome in ANCA-associated vasculitis, and also the mortality in these patients.
    Type of Medium: Online Resource
    ISSN: 0042-8450 , 2406-0720
    Language: English
    Publisher: National Library of Serbia
    Publication Date: 2021
    detail.hit.zdb_id: 2169819-3
    SSG: 15,3
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    Online Resource
    Online Resource
    Oxford University Press (OUP) ; 2019
    In:  Nephrology Dialysis Transplantation Vol. 34, No. Supplement_1 ( 2019-06-01)
    In: Nephrology Dialysis Transplantation, Oxford University Press (OUP), Vol. 34, No. Supplement_1 ( 2019-06-01)
    Type of Medium: Online Resource
    ISSN: 0931-0509 , 1460-2385
    Language: English
    Publisher: Oxford University Press (OUP)
    Publication Date: 2019
    detail.hit.zdb_id: 1465709-0
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 5
    In: Nephrology Dialysis Transplantation, Oxford University Press (OUP), Vol. 37, No. Supplement_3 ( 2022-05-03)
    Abstract: A 5-year research was conducted on haemodialysis patients with the aim to determine the effect of therapy on the patency of arteriovenous fistula (AVF) for haemodialysis. METHOD The study included 338 haemodialysis patients with the incidence of the creation of AVF in 2014. Patients were divided into two groups, according to the duration time of AVF namely short-term (≤6 months) and long-term ( & gt;6 months) patency. Clinical and laboratory parameters were analysed as well as type and frequency of complications, characteristics of AVF and treatment. The data were analysed with a chi-squared test, ANOVA test and an ordinally logistic regression. There was a statistical significance, P & lt;0.05. RESULTS From a total of 338 patients, the average age of 59.06 ± 12.45, 66.6% of patients were men. 80.7% of the patients were in the short-term group. Patients taking anti-platelet drugs make 14.8%, patients taking anticoagulation therapy and double anti-platelets therapy make 1.8%, patients taking statins, angiotensin-converting enzyme inhibitors (ACE)/angiotensin-receptor blockers (ARB) and calcium channel blockers make 47% and 2.6% of patients took no medication. The number of AVF complications was thrombosis in 19.1%, haemorrhage in 1.9%, aneurism and pseudoaneurysm in 0.5%, ‘Steal’ syndrome in 0.3%, infections in 0.3% and other complications in 2.2%. In accordance with the length of anti-platelets therapy (˂30 days, between 30 and 90 days, and ˃90 days) after the creation of AVF, it was concluded that the most influential effect was in the period between 30 and 90 days after creation. Patients with AVF for ˂6 months had significantly more vascular calcifications (P =.0017). The groups did not differ in the length of anti-platelets and anti-coagulation therapy before the creation of AVF ( & lt;1 year, & gt;1 year, no therapy), time of maturity of AVF (4–6 weeks, 6–8 weeks, ˃8 weeks), indications for reducing or stopping with anti-platelets or anticoagulation therapy in the moment of AVF creation. Four models of ordinally logistic regression (2015, 2016, 2017, 2018) were created in which the dependent variables were the complications of AVF by years, the factors were the type of treatment and the frequency of each complication for each year, while the covariate was the number of months after the AVF creation (Table). CONCLUSION Patients that started taking anti-platelets drugs from 30 to 90 days of AVF, had AVF for a significantly longer time. The model showed in years states that the frequency of complications decreases over time and that there are more infections and other complications than thrombosis and haemorrhage.
    Type of Medium: Online Resource
    ISSN: 0931-0509 , 1460-2385
    Language: English
    Publisher: Oxford University Press (OUP)
    Publication Date: 2022
    detail.hit.zdb_id: 1465709-0
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 6
    In: Nephrology Dialysis Transplantation, Oxford University Press (OUP), Vol. 38, No. Supplement_1 ( 2023-06-14)
    Abstract: End stage kidney disease (ESKD) is a well-recognized risk factor for cardiovascular and all-cause mortality. The recognition of high-risk patients could lead to a different approach and better treatment of the patients undergoing chronic hemodialysis. The CHA2DS2-VASc score was originally used to predict the annual cerebral infarction in patients with atrial fibrillation. However, it is also a useful predictor of outcome in other cardiovascular conditions, independent of atrial fibrillation. The aim of this study was to assess whether CHA2DS2-VASc score may be used as a risk stratification tool for ESKD patients undergoing chronic hemodialysis. Method We performed a single-centre retrospective study of 201 adult patients undergoing chronic hemodialysis in our institution from January 2020 to December 2022 with a follow up period of at least 12 months. CHA2DS2-VASc score was calculated for each patient according to the data from January 1st 2020 or at the moment of haemodialysis initiation, if the date of the first dialysis was after that date. Patients were followed until January 1st 2023, or until their death or kidney transplantation. Demographic, clinical and laboratory parameters, as well as used medications, were analyzed. Occurrences of myocardial infarction, stroke, revascularization procedure, new hospitalization for heart failure, cardiovascular death, or all-cause mortality were recorded for each patient. Patients were divided into three groups according to their CHA2DS2-VASc score: low (0-2), intermediate (3), high (≥4). Results The group with a low CHA2DS2-VASc score (0-2)-group I included 80 (39.8%) patients, the group with a intermediate score (3)-group II included 62 (30.8%) patients, and the group with a high score (≥4)-group III included 59 (29.4%) patients. Mean follow-up time was 918±317 days. Patients in the group with higher CHA2DS2-VASc scores (group III) were predominantly females (group III 62.7% vs group II 45.2% vs group I 23.8%; p & lt;0.01) and older (group III 74.9±7.4 years vs group II 68.7±7.6 years vs group I 55.2±11.3 years; p & lt;0.01). They also had a higher prevalence of diabetes mellitus (group III 61.0% vs group II 45.2% vs group I 21.3%; p & lt;0.01) and vascular disease (group III 30.5% vs group II 12.9% vs group I 3.8%; p & lt;0.01). Major adverse cardiovascular events (MACE) were significantly more prevalent in patients with higher CHA2DS2-VASc scores (p & lt;0.01) (Fig. 1). All-cause mortality was significantly higher in group II and group III, compared to the group I (p & lt;0.05) (Fig. 1). The patients in the group II and group III had a significantly higher risk of all-cause mortality and cardiovascular mortality than the patients in the group I (p & lt;0.05) (Fig. 2). Using a group I as a reference, group II and group III had a higher risk of all-cause mortality (HR 1.92, 95% CI 1.01-3.66, p & lt;0.05 and HR 2.47, 95% CI 1.32- 4.63, p & lt;0.01, respectively) and cardiovascular mortality (HR 3.56, 95% CI 1.18-9.53, p & lt;0.05 and HR 6.58, 95% CI 2.48-17.46, p & lt;0.001, respectively). Each one-point increase in CHA2DS2-VASc score was associated with a two-fold increased risk of MACE and a 47% increased risk of all-cause mortality. Conclusion The CHA2DS2-VASc score is a simple, easy-to-calculate tool that can be used to identify high-risk ESKD patients undergoing chronic hemodialysis. Clinical utilization of the CHA2DS2-VASc score in risk stratification of these patients could intensify patient care and lead to better outcomes by reducing cardiovascular morbidity and mortality and all-cause mortality.
    Type of Medium: Online Resource
    ISSN: 0931-0509 , 1460-2385
    Language: English
    Publisher: Oxford University Press (OUP)
    Publication Date: 2023
    detail.hit.zdb_id: 1465709-0
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 7
    Online Resource
    Online Resource
    Oxford University Press (OUP) ; 2020
    In:  Nephrology Dialysis Transplantation Vol. 35, No. Supplement_3 ( 2020-06-01)
    In: Nephrology Dialysis Transplantation, Oxford University Press (OUP), Vol. 35, No. Supplement_3 ( 2020-06-01)
    Abstract: Most patients with end stage renal disease (ESRD) initiate maintenance dialysis in three times per week regime irrespectively of residual kidney function (RKF). Incremental haemodialysis (IHD) showed benefits of starting and maintaining patients on less than three times per week regime, most importantly preserving urine volume output (UVO) and RKF. The aim of this study was to assess the main differences between a group of patients initiating dialysis once-weekly (1xHD) and twice-weekly (2xHD), to evaluate time to dialysis regime change, UVO and patients volume status at the end of study period. Method Patients with ESRD who started haemodialysis through the planned IHD (once-weekly and twice-weekly) and were undergoing IHD for at least 4 months (M) were enrolled (n=44) in the study. Study was conducted from January 2016 to December 2019 at dialysis department of our hospital. Patients were divided into two groups: 1xHD (20 pts) and 2xHD (24 pts). They were excluded from the study at the end of study period or earlier if they transitioned to thrice-weekly haemodialysis or died. Patients fluid status and body composition was assessed using results derived from bioimpedance measurements performed using Body Composition Monitor device. Results The 1xHD pts were younger (66,8±11,6 versus 67,4±10 years: P & gt;0.05) and weighed less (74,4±14,7 versus 75,5±11,9 kg, p & gt;0,05) with lower BMI. In both groups there were more males (60% versus 62,5%: P & gt;0,05). The most common cause of ESRD in both groups was nephrosclerosis (45% in 1xHD versus 47,1% in 2xHD, p & gt;0,05), followed by diabetic nephropathy (30% versus 20,8%, p & gt;0,05), obstructive nephropathy (10% versus 8,3%, p & gt;0,05), multiple myeloma (10% versus 8,3%, p & gt;0,05), glomerulonephritis (5% versus 8,3%, p & gt;0,05) and others in 2xHD group (12,5%; polycystic kidney disease and chronic interstitial nephritis). The estimated glomerular filtration rate of all patients at the time of HD initiation was 7,5±2,2 ml/min/1.73m2 (8,2±2,8 in 1xHD group versus 6,9±1,48 ml/ min/1.73m2 in 2xHD group, p & gt;0,05). Baseline daily urine output was similar, 1826,6±344,6 ml/day in 1xHD and 1772,2±343,8 ml/day in 2xHD group (p & gt;0,05). Patients in 1xHD concluded the study after mean period of 13,4 M (min 4 M, max 35 M). At the end of study period only three patients (15%) continued receiving dialysis once-weekly (mean 14,5 M, min 7 M, max 19 M), 12 pts (60%) transitioned to twice-weekly dialysis regime after 2 to 6 M (mean 3,1 M) and continued to receive this dialysis regime until the end of study period. Four pts (20%) transitioned to full-dose dialysis (mean 18,2 M, 11-24 M). Most of the patients in 2xHD group (17; 70,8%) concluded study in the same dialysis regime (mean 20,4 M, 4-24 M), 7 pts (29%) transitioned to full-dose dialysis (mean 12,6 M, 5-21 M) and one patient transitioned to once-weekly HD (8M). At the end of study daily urine output was 1463,1±317,5 in 1xHD versus 1321,1±309,1 ml/day in 2xHD group (p & gt;0,05). Results of assessment of fluid status and body composition at the end of study are in Table 1. We evaluated nutritional status at the end of study: total protein 57,4±8,9 g/l in 1xHD versus 62,8±5,3 g/l in 2xHD, albumin 36,9±10,6 versus 37,6±4,4 g/l, total cholesterol 4,1±1,6 versus 4,4±1,3 mmol/l, triglycerides 1,3±0,8 versus 1,7±0,7 mmol/l (p & gt;0,05 for all parameters). At the end of the study 70% of patients treated with IHD maintained renal function that was sufficient to continue IHD regime with overall survival rate 90% in 1xHD group and 87,5% in 2xHD group. Conclusion IHD, in carefully selected patients with good compliance, provides preservation of UVO and RKF, thus delaying transition to full-dose dialysis and avoiding complications of dialysis, such as intradialytic hypotension and vascular access failure. This type of dialysis is individualized treatment that obtains easier adaptation to dialysis and better quality of life.
    Type of Medium: Online Resource
    ISSN: 0931-0509 , 1460-2385
    Language: English
    Publisher: Oxford University Press (OUP)
    Publication Date: 2020
    detail.hit.zdb_id: 1465709-0
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 8
    Online Resource
    Online Resource
    Oxford University Press (OUP) ; 2020
    In:  Nephrology Dialysis Transplantation Vol. 35, No. Supplement_3 ( 2020-06-01)
    In: Nephrology Dialysis Transplantation, Oxford University Press (OUP), Vol. 35, No. Supplement_3 ( 2020-06-01)
    Abstract: Acute kidney injury (AKI) is common and serious complication in critically ill patients in intensive care unit (ICU). The rapid increase in aging populations with more comorbidities contribute to high incidence AKI in ICU. Incidence varies from 20% to as high as 70%. AKI in the ICU frequently requires costly supportive therapies, has high morbidity and it’s associated with poor outcomes. We aimed to determine incidence of AKI, causes, risk factors, treatment and outcomes of AKI in critically ill patients in ICU. Method We collected data prospectively from case records of adult patients (older than 18 years of age) admitted to the ICU at the Department of Internal medicine, Emergency Center, Clinical center of Vojvodina in Novi Sad, Serbia, during 3 months. We included patients who had at least two measurements of serum creatinine. Data on patient demographics, diagnosis at the time of ICU admission, complete blood count, biochemistry, comorbidities (diabetes mellitus, arterial hypertension, other cardiovascular diseases, renal disease, prostate diseases, dehydration, burns, gastrointestinal bleeding, pancreatitis, peritonitis, sepsis), use of nephrotoxic agents, radiological procedures and treatment of AKI were recorded. We excluded patients with chronic renal disease who were on hemodialysis. There were no interventions. Results Of the 44 patients included in the study, median age was 67+/-13,20 years (range: 21 to 88). Of those 44 patients 20% developed AKI. De novo AKI was diagnosed in 51,22% of those patients and 48,78% had chronic renal failure in acutisation. The most frequent etiology was pre-renal, in 80,95% of patients. Renal origin and obstructive (post-renal) causes were detected in the same number of patients, 9,52%. Comorbidities were present present in all patients. Most common comorbidity was arterial hypertension, in 52,4% of patients, other cardiovascular diseases in 47,6 % of patients, sepsis also in 47,6% of patients and gastrointestinal bleeding in 33,3% of patients. Complete recovery of kidney function was detected in 42,86% of patients. Mortality was 28,57%. During the hospitalisation 90,48% of patients were treated conservative and 9,52% of patients required renal replacement therapy. Conclusion De novo AKI occurred in approximately half of the critically ill patients in ICU. The most frequent etiology was pre-renal. AKI was mainly detected in older patients with comorbidities. Age and comorbidities were also associated with the poor outcome. Mortality was high.
    Type of Medium: Online Resource
    ISSN: 0931-0509 , 1460-2385
    Language: English
    Publisher: Oxford University Press (OUP)
    Publication Date: 2020
    detail.hit.zdb_id: 1465709-0
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 9
    In: Nephrology Dialysis Transplantation, Oxford University Press (OUP), Vol. 36, No. Supplement_1 ( 2021-05-29)
    Abstract: Critically ill patients with acute renal impairment (AKI) with a high risk of bleeding require treatment with one of the methods of continuous renal replacement (CRRT) with regional citrate anticoagulation (RCA) or without anticoagulation (NA). The aim of the study was to compare CRRT with RCA using calcium with CRRT in NA regimen. Method A clinical trial included 55 surgical and non-surgical patients with acute kidney injury and an episode of acute kidney injury in chronic kidney disease who were admitted to the Intensive Care Unit (ICU) during 2020. The patients were divided into two groups, RCA- CRRT with 39 and NA-CRRT with 16 patients. Demographic, clinical and lab data before and after CRRT, treatment parameters CRRT and outcomes were analyzed. Results RCA vs NA group did not differ significantly by gender (small, 71.79% vs 56.25%, p = 0.106) and age (56.53 ± 17.55 vs 45.75 ± 13.3, p = 0.220). The NA group had a significantly higher prevalence of liver disease as a reason for the ICU admission when compared to the other group (12.5% vs 0.00%, p = 0.024). The RCA group before CRRT had significantly higher mean values of CRP (173.68 ± 122.06 vs 86.33 ± 51.05, p = 0.01) and significantly lower mean values of total bilirubin (16.78 ± 4.31 vs 40.02 ± 9.22, p = 0.005) and creatinine (463.97 ± 36.24 vs 486.0 ± 36.25, p = 0.001), while after CRRT it had significantly higher average values of total calcium (2.12 ± 0.016 vs 2.11 ± 0.017, p = 0.023) and lower average values of pH (7.29 ± 0.02 vs 7.32 ± 0.015, p = 0.040) and creatinine (463.97 ± 36.24 vs 486.0 ± 36.25, p = 0.001) in relation to the NA group. No significant difference was found in relation to invasive mechanical ventilation, vasopressors therapy, SAPS II score, oliguria / anuria, recovery of renal function, the length of hospital stay and mortality (p & gt; 0.05) (Table 1). Compared to treatment parameters, the RCA group had a significantly lower number of procedures (4.33 ± 2.80 vs 5.81 ± 1.28, p = 0.027) and ultrafiltration rate (2.79 ± 0.19 vs 3.14 ± 0.33, p = 0.015) and significantly longer hemofilter lifespan compared to NA group (24.64 ± 0.48 vs 18.10 ± 0.58, p = 0.000). Although the prevalence of bleeding was higher in the NA group, no significant difference was found between the groups (37.5% vs 28.20%, p = 0.498), as well as in the infusion of red blood cell (33.3% vs 37.5%, p = 0.768), fresh frozen plasma (28.2% vs 50%, p = 0.742) and platelets (35.89 vs 31.25, p = 0.123). The overall citrate accumulation (CA & gt; 2.25) rate was 5.12% in the RCA group (Table 2). The Kaplan-Meier survival analysis using the log-rank test (Mantel-Cox test) for comparing the hemofilter lifespan between RCA and NA regime found a significant difference in survival between the groups (χ2 = 3,789, p = 0,049) (Figure 1). Multiple regression model for testing risk factors SAPS II score, Oxiris membrane, UF, lactate, hemoglobin concentration, platelet count, Activated Partial Thromboplastin Time and Prothrombin Time on hemofilter survival has shown a significant linear relationship without statistical significance in both RCA groups (R=0.544 ; F=1.575) and NA (R=0.757; F=1.171) (Table 3). Conclusion RCA-CRRT did not show a significant difference in the prevalence of bleeding compared to NA-CRRT in the patients with a high risk of bleeding, but the survival rate of hemofilters was significantly longer in RCA-CRRT, which suggested the need for further research.
    Type of Medium: Online Resource
    ISSN: 0931-0509 , 1460-2385
    Language: English
    Publisher: Oxford University Press (OUP)
    Publication Date: 2021
    detail.hit.zdb_id: 1465709-0
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 10
    In: Nephrology Dialysis Transplantation, Oxford University Press (OUP), Vol. 36, No. 11 ( 2021-11-09), p. 2094-2105
    Abstract: Coronavirus disease 2019 (COVID-19) has exposed haemodialysis (HD) patients and kidney transplant (KT) recipients to an unprecedented life-threatening infectious disease, raising concerns about kidney replacement therapy (KRT) strategy during the pandemic. This study investigated the association of the type of KRT with COVID-19 severity, adjusting for differences in individual characteristics. Methods Data on KT recipients and HD patients diagnosed with COVID-19 between 1 February 2020 and 1 December 2020 were retrieved from the European Renal Association COVID-19 Database. Cox regression models adjusted for age, sex, frailty and comorbidities were used to estimate hazard ratios (HRs) for 28-day mortality risk in all patients and in the subsets that were tested because of symptoms. Results A total of 1670 patients (496 functional KT and 1174 HD) were included; 16.9% of KT and 23.9% of HD patients died within 28 days of presentation. The unadjusted 28-day mortality risk was 33% lower in KT recipients compared with HD patients {HR 0.67 [95% confidence interval (CI) 0.52–0.85]}. In a fully adjusted model, the risk was 78% higher in KT recipients [HR 1.78 (95% CI 1.22–2.61)] compared with HD patients. This association was similar in patients tested because of symptoms [fully adjusted model HR 2.00 (95% CI 1.31–3.06)]. This risk was dramatically increased during the first post-transplant year. Results were similar for other endpoints (e.g. hospitalization, intensive care unit admission and mortality & gt;28 days) and across subgroups. Conclusions KT recipients had a greater risk of a more severe course of COVID-19 compared with HD patients, therefore they require specific infection mitigation strategies.
    Type of Medium: Online Resource
    ISSN: 0931-0509 , 1460-2385
    Language: English
    Publisher: Oxford University Press (OUP)
    Publication Date: 2021
    detail.hit.zdb_id: 1465709-0
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. Further information can be found on the KOBV privacy pages